US4522949A
Expired / Lapsed
US
⏱️ 0.0 years remaining
7-Oxabicycloheptane substituted prostaglandin interphenylene analogs useful as cardiovascular agents
Assignee: ER Squibb and Sons LLC
•
Filing: 1983-10-20
•
Granted: 1985-06-11
•
Expires: 2003-10-20
Abstract
Abstract 7-Oxabicycloheptane substituted interphenylene prostaglandin analogs are provided having the structural formula ##STR1## and including all stereoisomers thereof. The compounds are cardiovascular agents useful, for example, in the treatment of thrombolytic disease.
Inventors
- 👤 Jagabandhu Das
- 👤 Martin F. Haslanger
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 22:39
CPC Classifications
C; C07; C07D; C07D493/00; C07D493/02; C07D493/08; A; A61; A61P; A61P11/00; A61P43/00; A61P7/00; A61P7/02
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
168 words
A compound having the structural formula ##STR30## and including all stereoisomers thereof; wherein A is CH═CH or (CH 2 ) 2 ; m is 1 to 4; n is 1 to 8; R is H, lower alkyl or alkali metal; and R 1 is lower alkyl, aryl, aralkyl, cycloalkyl or cycloalkylalkyl; wherein the term lower alkyl or alkyl by itself or as part of another group is unsubstituted or substituted with halo, trifluoromethyl, alkoxy, aryl, alkyl-aryl, haloaryl, cycloalkyl or alkylcycloalkyl; the term aryl by itself or as part of another group contains 6 to 10 carbons and is unsubstituted or substituted with lower alkyl, halogen or lower alkoxy; and the term cycloalkyl by itself or as part of another group contains 3 to 12 carbons and is unsubstituted or substituted with 1 or 2 halogens, 1 or 2 lower alkyl groups and/or 1 or 2 lower alkoxy groups; and wherein (CH 2 ) m and (CH 2 ) n may be substituted by one or more alkyl substituents.
Claim 2
Dependent Claim
168 words
A compound having the structural formula ##STR30## and including all stereoisomers thereof; wherein A is CH═CH or (CH 2 ) 2 ; m is 1 to 4; n is 1 to 8; R is H, lower alkyl or alkali metal; and R 1 is lower alkyl, aryl, aralkyl, cycloalkyl or cycloalkylalkyl; wherein the term lower alkyl or alkyl by itself or as part of another group is unsubstituted or substituted with halo, trifluoromethyl, alkoxy, aryl, alkyl-aryl, haloaryl, cycloalkyl or alkylcycloalkyl; the term aryl by itself or as part of another group contains 6 to 10 carbons and is unsubstituted or substituted with lower alkyl, halogen or lower alkoxy; and the term cycloalkyl by itself or as part of another group contains 3 to 12 carbons and is unsubstituted or substituted with 1 or 2 halogens, 1 or 2 lower alkyl groups and/or 1 or 2 lower alkoxy groups; and wherein (CH 2 ) m and (CH 2 ) n may be substituted by one or more alkyl substituents.
Claim 3
Dependent Claim
24 words
The compound as defined in claim 1 having the formula ##STR31## wherein R is hydrogen, R 1 is lower alkyl, including all stereoisomers thereof.
Claim 4
Dependent Claim
11 words
The compound as defined in claim 1 having the formula ##STR32##
Claim 5
Dependent Claim
15 words
The compound as defined in claim 1 wherein m is 1 and n is 1.
Claim 6
Dependent Claim
11 words
The compound as defined in claim 1 wherein A is CH═CH.
Claim 7
Dependent Claim
17 words
The compound as defined in claim 4 wherein R 1 is butyl, pentyl, hexyl, heptyl or 1,1-dimethylpentyl.
Claim 8
Dependent Claim
21 words
The compound as defined in claim 1 having the name [1α,2β,3β(1E,3R),4α]-[3-[[3-(3-hydroxy-4,4-dimethyl-1-octenyl)-7-oxabicyclo[2.2.1]hept-2-yl]methyl]phenoxy]acetic acid or the methyl ester thereof, including all stereoisomers thereof.
Claim 9
Dependent Claim
38 words
A method of inhibiting arachidonic acid-induced platelet aggregation and bronchoconstriction, which comprises administering to the circulatory system of a mammalian host an effective amount of a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof.
Claim 10
Dependent Claim
26 words
The method as defined in claim 8 wherein said compound is administered in an amount within the range of from about 1 to about 100 mg/kg.
Claim 11
Dependent Claim
34 words
A composition for inhibiting arachidonic acid-induced platelet aggregation and bronchoconstriction comprising an effective amount of a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier thereof.
Claim 12
Dependent Claim
32 words
A method of inhibiting bronchoconstriction associated with asthma, which comprises administering to a mammalian host an effective amount of a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof.
Claim 13
Dependent Claim
34 words
A method for treating peripheral vascular disease, which comprises topically or systemically administering to a mammalian host an effective amount of a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof.
References Cited (Backward Citations)
US4143054A
Cited
US4187236A
Cited
US4220594A
Cited
US4254044A
Cited
GB2039909A
Cited
US4228180A
Cited
EP0043292A2
Cited
US4463015A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-06-10 | 1988-12-10 | 1989-06-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-06-10 | 1992-12-10 | 1993-06-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-06-10 | 1996-12-10 | 1997-06-11 | $7700.00 | Window Closed / Lapsed |